Clinical trials: COPD Patients
COPD, Acute Respiratory Failure
Revefenacin in Acute Respiratory Insufficiency in COPD
RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory…
- Trial name
- RARICO (NCT04315558)
- Testing
- Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of California, Los Angeles
COPD
Nurse Coach-Led Early Palliative Care for Older Adults With COPD and Their Care Partners: The Project EPIC Pilot RCT
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in older Americans. COPD increases in frequency with age, and older adults with COPD often have significant unmet geriatrics-palliative care needs…
- Trial name
- NCT05040386
- Testing
- EPIC (Empower People to Independence in COPD), Usual Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Alabama at Birmingham
COPD
RESP-FIT: Technology-Enhanced Self-Management in COPD
30 adults, aged 40 and older with mild to moderate COPD, will be recruited for this study. Participants must be willing to continually wear a FitBit activity monitor, have access to a smartphone or Wi-Fi/Data-enabled iPad, and be…
- Trial name
- RESP-FIT (NCT03652662)
- Testing
- RESP-FIT, RESP-FIT Comparator
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Medical University of South Carolina
COPD, Asthma
LungVITamin D and OmegA-3 Trial (lungVITAL)
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids…
- Conditions
- COPD, Asthma, Pulmonary Function, Pneumonia
- Trial name
- lungVITAL (NCT01728571)
- Testing
- Vitamin D3, fish oil
- Where
- United States
- Volunteers
- 25,871 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
COPD
Effectiveness of Standardized Respiratory Physiotherapy in Primary Care (FREAP)
Chronic Obstructive Pulmonary Disease (COPD) is a very important public health problem and one of the most common lung diseases in the world, with repercussions on mortality and high economic costs.
- Trial name
- FREAP (NCT01152762)
- Testing
- Standardized Respiratory Physiotherapy
- Where
- Spain
- Volunteers
- 129 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
COPD Exacerbation
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized…
- Trial name
- NCT04655170
- Testing
- Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Tennessee Graduate School of Medicine
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via…
- Trial name
- TRILOGY (NCT01917331)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate, Beclometasone/Formoterol
- Where
- Hungary
- Volunteers
- 1,368 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD (Chronic Obstructive Pulmonary Disease)
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
Primary Objective To demonstrate the superiority of CHF 5993 pressurised metered dose inhaler (pMDI) over Symbicort® Turbuhaler® in terms of pulmonary function (change from baseline in pre-dose morning forced expiratory volume in…
- Trial name
- TRIVERSYTI (NCT03197818)
- Testing
- CHF 5993 100/6/12.5 µg, 160 µg budesonide + 4.5 µg formoterol fumarate
- Where
- 64 sites in China, South Korea and 1 more
- Volunteers
- 708 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Stroke (CVA) or TIA, Diabetes
Risk Factors, Costs, and Impacts of ED Boarding
The goal of this observational study is to learn about the risk factors, costs, and operational impacts of emergency department boarding (patients admitted to the hospital but remaining in the emergency department awaiting…
- Conditions
- Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease)
- Trial name
- NCT07532564
- Where
- United States
- Volunteers
- 30,486 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
COPD, Emphysema
Anti-Platelets in Chronic Obstructive Pulmonary Disease
This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e.
- Conditions
- COPD, Emphysema, Emphysema or COPD
- Trial name
- NCT05567562
- Testing
- dual anti-platelet therapy
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
COPD
A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD
The investigators aim to recruit 32 people with COPD who have frequent exacerbations and high eosinophil counts which indicates "asthmatic type" inflammation and treat them for a year with mepolizumab.
- Trial name
- SUMMER (NCT05138250)
- Testing
- Mepolizumab 100 MG
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
COPD, Eosinophilia
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.
- Trial name
- COPD-HELP (NCT04075331)
- Testing
- Mepolizumab
- Where
- United Kingdom
- Volunteers
- 238 people
- Sponsor
- University of Leicester
COPD
COPD Access to Pulmonary Rehabilitation Intervention
Persons with COPD have significant functional disability but cannot access rehabilitative treatment at hospital-based conventional pulmonary rehabilitation (PR) programs.
- Trial name
- CAPRI (NCT03794921)
- Testing
- Every Step Counts
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- VA Office of Research and Development
COPD Exacerbation
Increasing Adherence to Pulmonary Rehabilitation After COPD Related Hospitalizations (Study 2)
This study is being done to test the comparative effectiveness of participating in a Pulmonary Rehabilitation Program at home using new technology and health coaching following dismissal from the hospital compared to the referral…
- Trial name
- NCT04521608
- Testing
- Intervention- Home-based Pulmonary Rehabilitation
- Where
- 2 sites in United States
- Volunteers
- 296 people
- Sponsor
- Mayo Clinic
Copd
Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations
This is a single-center, prospective, open-label study evaluating outcomes of TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder) on PRN nebulized short-acting beta…
- Trial name
- Sundial-COPD (NCT05292053)
- Testing
- TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Baylor Research Institute
COPD Asthma
Pulmonary Specialist-Health Coach Consult Model Study
The Pulmonary Specialist-Health Coach Consultation (PuSHCon) study examines the implementation of health coach-assisted consultations to improve access to specialist care and implementation of specialist recommendations for…
- Trial name
- PuSHCon (NCT03695276)
- Testing
- PushCon Model, Usual care
- Where
- 11 sites in United States
- Volunteers
- 328 people
- Sponsor
- University of California, San Francisco
COPD
Acupuncture to Enhance for Pulmonary Rehab
The investigator is investigating if acupuncture may improve pulmonary function, exercise tolerance, stress and modulate the inflammatory effects of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04947800
- Testing
- Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36, Pulmonary rehabilitation program + Lv7/Gb26
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Chronic Obstructive Pulmonary Disease (COPD)
Lung Imaging of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)
This is a prospective interventional study examining the use of Annexin - a radioactive tracer, in assessing lung damage in healthy volunteers, healthy volunteers actively smoking, and patients with moderate and severe chronic…
- Trial name
- NCT02978144
- Testing
- AxV-128/Tc
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Columbia University
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
COPD, Chronic Obstructive Pulmonary Disease
Motivational Interviewing and Air Cleaners for Smokers With COPD (MOVE COPD)
COPD is characterized by lung injury and inflammation caused by noxious particles and gases, including those emanating from cigarette smoke and air pollution.
- Trial name
- MOVE-COPD (NCT03658538)
- Testing
- Active HEPA Air Cleaner, Motivational interviewing
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Johns Hopkins University